公开(公告)号：US20110014211A1

公开(公告)日：2011-01-20

申请号：US12864018

申请日：2009-01-23

申请人： Masachika Azuma ,  Motohide Takahashi ,  Shunji Kozaki ,  Masafumi Mukamoto ,  Tomoko Kohda ,  Gene Kurosawa ,  Yoshikazu Kurosawa

发明人： Masachika Azuma ,  Motohide Takahashi ,  Shunji Kozaki ,  Masafumi Mukamoto ,  Tomoko Kohda ,  Gene Kurosawa ,  Yoshikazu Kurosawa

IPC分类号： A61K39/40 ,  A61P31/04

CPC分类号： C07K16/1282 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.

摘要翻译： 本文提供了对肉毒中毒疾病和预防肉毒杆菌病有效的手段。 具体提供的是具有彼此具有不同表位的多种人类抗 - 肉毒毒素A型抗体。 还具体提供了用于中和A型肉毒杆菌毒素的组合物，其包含两种或更多种抗体的组合并且具有高中和活性。

公开(公告)号：US09598496B2

公开(公告)日：2017-03-21

申请号：US14116714

申请日：2012-05-07

申请人： Yoshikazu Kurosawa ,  Kazuhiro Morishita ,  Lilin Zhang ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Yukio Sudo ,  Fumiko Nomura ,  Yoshinori Ukai

发明人： Yoshikazu Kurosawa ,  Kazuhiro Morishita ,  Lilin Zhang ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Yukio Sudo ,  Fumiko Nomura ,  Yoshinori Ukai

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/30 ,  C07K16/2881

摘要： An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).

公开(公告)号：US09534042B2

公开(公告)日：2017-01-03

申请号：US13198147

申请日：2011-08-04

申请人： Yoshikazu Kurosawa ,  Yoshitaka Iba ,  Nobuko Ohshima ,  Yoshinobu Okuno

发明人： Yoshikazu Kurosawa ,  Yoshitaka Iba ,  Nobuko Ohshima ,  Yoshinobu Okuno

IPC分类号： C07K16/28 ,  C07K16/10 ,  A61K39/395 ,  A61K47/48 ,  C07K16/30 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/00

摘要： Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

摘要翻译： 本发明提供了抗血清病毒抗体，其表现出根据血凝素氨基酸的保守性分类的两组流感病毒的屏障之外的中和活性，其生产方法，以及用于确定受试者是否携带 中和抗体。

公开(公告)号：US20140114054A1

公开(公告)日：2014-04-24

申请号：US14116714

申请日：2012-05-07

申请人： Yoshikazu Kurosawa ,  Kazuhiro Morishita ,  Lilin Zhang ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Yukio Sudo ,  Fumiko Nomura ,  Yoshinori Ukai

发明人： Yoshikazu Kurosawa ,  Kazuhiro Morishita ,  Lilin Zhang ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Yukio Sudo ,  Fumiko Nomura ,  Yoshinori Ukai

IPC分类号： C07K16/30

CPC分类号： C07K16/30 ,  C07K16/2881

摘要： An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).

摘要翻译： 本发明的目的是提供一种完全人抗TfR抗体，其特异性识别人TfR，抑制高表达TfR的癌细胞的存活或生长，并且对人类没有免疫原性。 本发明提供与人TfR特异性反应的抗体，其中所述抗体包含SEQ ID NO： 31-33,37-39,43-45,49-51,55-57,61-63,67-69,73-75,79-81,85-87,91-93,97-99,103- 105，109-111和115-117，作为重链第一互补决定区（VH CDR1），重链第二互补决定区（VH CDR2）和重链第三互补决定区（VH CDR3） 。